RP
ALXN

Richard Pzena’s Alexion Pharmaceuticals ALXN Stock Holding History

Richard Pzena’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,430
Closed -$630K – 177
2021
Q2 		$630K Sell
3,430
-795
-19% -$136K ﹤0.01% 138
2021
Q1 		$646K Buy
4,225
+176
+4% +$27.2K ﹤0.01% 151
2020
Q4 		$633K Sell
4,049
-874
-18% -$112K ﹤0.01% 152
2020
Q3 		$563K Sell
4,923
-1,062
-18% -$115K ﹤0.01% 148
2020
Q2 		$672K Sell
5,985
-1,632
-21% -$173K ﹤0.01% 152
2020
Q1 		$684K Buy
+7,617
New +$748K 0.01% 148

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Richard Pzena's ALXN Position: Q3 2021 in Review

Richard Pzena sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,430 shares — an estimated $630K sold.

Richard Pzena first reported a position in ALXN in Q1 2020 and held it in 6 quarters. The position peaked at $684K in Q1 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Richard Pzena reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Richard Pzena sold 3,430 Alexion Pharmaceuticals shares in Q3 2021, an estimated $630K.
  • Richard Pzena first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 6 quarters.
  • Richard Pzena's Alexion Pharmaceuticals position peaked at $684K in Q1 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Pzena Investment Management's 13F filing for Q3 2021, filed 5 Nov 2021.